Gujarat Themis Biosyn Approves Q3 Unaudited Results; Appoints New CFO
Gujarat Themis Biosyn approved unaudited Q3 results. Ms. Kirandeep Madan reappointed as Independent Director from May 1, 2026. Mr. Krupesh Patel appointed CFO from April 1, 2026, replacing Mr. Bhavik Shah who transitions to a new role.
The appointment of a new CFO and the re-appointment of an independent director are significant for corporate governance and financial operations, thus having a medium impact.
The announcement includes routine financial results and standard management changes, with no significant positive or negative developments impacting the company's outlook.
Gujarat Themis Biosyn Limited announced its unaudited financial results for the quarter and nine months ended December 31, 2025. The company's Board of Directors, in a meeting held on February 5, 2026, approved these results along with the limited review report from M/s. GMJ & Co.
In significant management changes, the Board approved the re-appointment of Ms. Kirandeep Madan as Non-Executive Woman Independent Director for a second term of five years, effective May 1, 2026, subject to shareholder approval. Additionally, Mr. Bhavik Shah will transition from his role as Chief Financial Officer (CFO) to a different position within the company focusing on plant-related accounting activities. Consequently, Mr. Krupesh Patel has been appointed as the new CFO and Key Managerial Personnel (KMP), effective April 1, 2026. Mr. Patel brings 15 years of experience across various sectors and holds an MBA (Finance), is a Cost and Management Accountant (ICWA), Company Secretary (CS), and holds a law degree.
What to do with a filing like this
Gujarat Themis Biosyn Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gujarat Themis Biosyn Limited. Read the original for the full detail.